FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000000998> ?p ?o ?g. }

• W3000000998 abstract "Oral administration of drugs is the most common, convenient, safest and economical route of drug administration. There is lack of established tools to study the function of transporters in the intestinal absorption of drugs. Because of its favorable physico-chemical, pharmacokinetic and pharmacodynamic characteristics, trospium could be potentially used as a probe substrate to study the function of drug transporters. Therefore, this study was conducted to examine the suitability of trospium chloride as a probe drug to study the function of multidrug transporters in the human body. To this end, two randomized, controlled, four-period, cross-over pharmacokinetic drug interaction studies of oral and intravenous trospium with co-medication of oral clarithromycin or ranitidine were performed in 24 healthy subjects to mechanistically characterize the role of P-gp, OATP1A2, OCT1, OCT2, MATE1 and MATE2-K in the absorption and disposition of trospium. The contribution of the drug transporters in the absorption and disposition of trospium were examined in isolated systems using in vitro uptake and inhibition assays in transporter transfected human cell lines. OCT1 (Vmax = 0.8 ± 0.1 nmol/min × mg) is a high capacity transporter of trospium compared to OCT2 (Vmax = 0.04 ± 0.01 nmol/min × mg). But the OCT2 (Km = 0.5 ± 0.1 µM) transporter demonstrated a high affinity in the transport of trospium compared to OCT1 (Km = 17.4 ± 2.1 µM). OCT1 genetic alleles *2, *3, *4 and *7 resulted in significant loss of activity and the alleles *5 and *6 caused complete loss of uptake of trospium. The common OCT2 genetic allele Ser270 caused slight but significant increase in activity of OCT2. Ranitidine inhibits OCT1 (IC50 = 186 ± 25 µM), MATE1 (IC50 = 134 ± 37 µM) and MATE2-K (IC50 = 35 ± 11 µM)-mediated uptake of trospium in vitro. But it is a weak inhibitor of OCT2 transporter (IC50 = 482 ± 105 µM). Using FDA and EMA in vitro to in vivo extrapolation models, ranitidine was predicted to have a potential inhibition effect on intestinal OCT1 ([I]2/IC50 ~40), renal MATE1 ([I]1/IC50 ~0.02) and MATE2-K ([I]1/IC50 ~0.1) transporters in vivo. Clarithromycin was predicted to cause DDI by inhibiting P-gp-mediated efflux of trospium at the intestine ([I]2/IC50 of ~310) and hepatocytes ([I]3/IC50 ~1). Therefore, co-medication of oral clarithromycin was expected to result in an increase in oral absorption and hepatic clearance of trospium but not changes in distribution volume. In healthy subjects, oral trospium is slowly (MAT ~10 h) and poorly (F ~10 %) absorbed from the jejunum and cecum/ascending colon, widely distributed into the body (Vss = 5 - 6 l/kg) and slowly eliminated (t1/2 = 9 - 10 h) majorly via renal glomerular filtration and tubular secretion (CLR ~500 ml/min). After co-medication of clarithromycin (inhibitor of P-gp), on the contrary to our IVIVE prediction, we found a non-expected but significant expansion of the shallow and deep distribution spaces for trospium by ~27 %. A single dose administration of trospium with co-medication of ranitidine (inhibitor of OCT1) resulted in no effect on the intestinal absorption of trospium. But the renal clearance of trospium decreased slightly (15 %) but significantly. Intravenously administered trospium (2 mg TC) might be a suitable probe drug to evaluate the effects of a P-gp inhibitor on distribution of a drug. Oral trospium chloride can be selected for DDI studies with new chemical entities (NCE) with predicted inhibitory potential on OCT1 and P-gp and which are available after oral absorption along the small intestine and in the cecum/ascending colon. Another kind of application of trospium chloride might be pharmacogenomics studies in subjects with functionally relevant polymorphisms of P-gp and OCT1 or in patients with suspected transport failure due to intestinal diseases. The function of the efflux transporters MATE1 and MATE2-K in the PTC of the kidneys can be well assessed with the probe drug trospium by measuring its renal clearance." @default.
• W3000000998 created "2020-01-23" @default.
• W3000000998 creator A5061168065 @default.
• W3000000998 date "2020-01-07" @default.
• W3000000998 modified "2023-09-27" @default.
• W3000000998 title "In Vitro to In Vivo Extrapolation of Pharmacokinetic Drug Interactions between Clarithromycin and Ranitidine with Trospium Chloride to Evaluate Probe Drug Characteristics for P-glycoprotein and Organic Cation Transporter Functions in Human" @default.
• W3000000998 hasPublicationYear "2020" @default.
• W3000000998 type Work @default.
• W3000000998 sameAs 3000000998 @default.
• W3000000998 citedByCount "0" @default.
• W3000000998 crossrefType "journal-article" @default.
• W3000000998 hasAuthorship W3000000998A5061168065 @default.
• W3000000998 hasConcept C104317684 @default.
• W3000000998 hasConcept C112705442 @default.
• W3000000998 hasConcept C149011108 @default.
• W3000000998 hasConcept C150903083 @default.
• W3000000998 hasConcept C185592680 @default.
• W3000000998 hasConcept C189613389 @default.
• W3000000998 hasConcept C207001950 @default.
• W3000000998 hasConcept C2777445857 @default.
• W3000000998 hasConcept C2780035454 @default.
• W3000000998 hasConcept C55493867 @default.
• W3000000998 hasConcept C71924100 @default.
• W3000000998 hasConcept C86803240 @default.
• W3000000998 hasConcept C97320921 @default.
• W3000000998 hasConcept C98274493 @default.
• W3000000998 hasConceptScore W3000000998C104317684 @default.
• W3000000998 hasConceptScore W3000000998C112705442 @default.
• W3000000998 hasConceptScore W3000000998C149011108 @default.
• W3000000998 hasConceptScore W3000000998C150903083 @default.
• W3000000998 hasConceptScore W3000000998C185592680 @default.
• W3000000998 hasConceptScore W3000000998C189613389 @default.
• W3000000998 hasConceptScore W3000000998C207001950 @default.
• W3000000998 hasConceptScore W3000000998C2777445857 @default.
• W3000000998 hasConceptScore W3000000998C2780035454 @default.
• W3000000998 hasConceptScore W3000000998C55493867 @default.
• W3000000998 hasConceptScore W3000000998C71924100 @default.
• W3000000998 hasConceptScore W3000000998C86803240 @default.
• W3000000998 hasConceptScore W3000000998C97320921 @default.
• W3000000998 hasConceptScore W3000000998C98274493 @default.
• W3000000998 hasLocation W30000009981 @default.
• W3000000998 hasOpenAccess W3000000998 @default.
• W3000000998 hasPrimaryLocation W30000009981 @default.
• W3000000998 hasRelatedWork W1582071385 @default.
• W3000000998 hasRelatedWork W1943293378 @default.
• W3000000998 hasRelatedWork W2035133162 @default.
• W3000000998 hasRelatedWork W2073025491 @default.
• W3000000998 hasRelatedWork W2143990875 @default.
• W3000000998 hasRelatedWork W2759481338 @default.
• W3000000998 hasRelatedWork W2796302271 @default.
• W3000000998 hasRelatedWork W2907565525 @default.
• W3000000998 hasRelatedWork W2918327537 @default.
• W3000000998 hasRelatedWork W2974030195 @default.
• W3000000998 hasRelatedWork W2985129586 @default.
• W3000000998 hasRelatedWork W2994205922 @default.
• W3000000998 hasRelatedWork W2996395230 @default.
• W3000000998 hasRelatedWork W3007927631 @default.
• W3000000998 hasRelatedWork W3009840573 @default.
• W3000000998 hasRelatedWork W3029204933 @default.
• W3000000998 hasRelatedWork W3031488383 @default.
• W3000000998 hasRelatedWork W3033056501 @default.
• W3000000998 hasRelatedWork W3081993672 @default.
• W3000000998 hasRelatedWork W3198550208 @default.
• W3000000998 isParatext "false" @default.
• W3000000998 isRetracted "false" @default.
• W3000000998 magId "3000000998" @default.
• W3000000998 workType "article" @default.